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Objectives The purpose of this study was to determine the association of family history of peripheral artery disease (PAD) with
PAD prevalence and severity.
Background PAD is a significant public health problem. Shared genetic and environmental factors may play an important
role in the development of PAD. However, family history of PAD has not been investigated adequately.
Methods The San Diego Population Study enrolled 2,404 ethnically diverse men and women 29 to 91 years of age who
attended a baseline visit from 1994 through 1998 to assess PAD and venous disease. Ankle brachial index
measurement was performed at the baseline clinic examination, and family history of PAD was obtained via
questionnaire. Family history of PAD was defined primarily as having any first-degree relative with PAD. Preva-
lent PAD was defined as ankle brachial index 0.90, and severe prevalent PAD was defined as ankle brachial
index 0.70, with both definitions also including any previous leg revascularization. Logistic regression was used
to evaluate the association of family history of PAD with prevalent PAD.
Results The mean age was 59  11 years, 66% were women, and 58% were Caucasian, with 42% representing other
racial or ethnic groups. Prevalence of PAD was 3.6%, and severe prevalent PAD was 1.9%. In fully adjusted mod-
els, family history of PAD was associated with a 1.83-fold higher odds of PAD (95% confidence interval: 1.03 to
3.26, p  0.04), an association that was stronger for severe prevalent PAD (odds ratio: 2.42, 95% confidence
interval: 1.13 to 5.23, p  0.02).
Conclusions Family history of PAD is independently strongly associated with PAD prevalence and severity. This indicates a
role for genetic factors or other shared environmental factors, or both, contributing to PAD. (J Am Coll Cardiol
2011;58:1386–92) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.023Peripheral artery disease (PAD) is a significant public health
issue, with approximately 8.5 million Americans currently
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accepted June 14, 2011.affected (1). PAD is associated with an increased risk of
cardiovascular events and mortality (2–5). Morbidities re-
sulting from PAD, including functional decline, intermit-
tent claudication, critical leg ischemia, and amputation,
severely affect quality of life (6–9). PAD prevalence differs
by racial and ethnic group, with African Americans having
the highest prevalence (10). Several studies have evaluated
potential explanatory factors for this higher prevalence in
African Americans and consistently have concluded that it
cannot be explained entirely by differences in traditional or
novel cardiovascular disease (CVD) risk factors (1,11–14).
This result may indicate that genetic factors are important
in the development of PAD.
Genes, environment, and the interaction of these factors
likely play a role in the development of PAD. However, few
genetic variants have been associated consistently with PAD
(15). Familial aggregation also is likely an important factor
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ciation of family history of PAD with prevalent PAD
largely is unknown. To our knowledge, only 2 small studies
have previously examined this association, but only evalu-
ated premature-onset PAD (49 years of age), and both
were conducted in samples consisting almost exclusively of
individuals of European descent (17,18).
Thus, we examined the association of family history of
PAD with prevalent PAD in a large, ethnically diverse
cohort of men and women 29 to 91 years of age who were
participants in the San Diego Population Study. Addition-
ally, we examined the association of family history of PAD
with prevalent CVD and family history of CVD with
prevalent PAD in this cohort.
Methods
Study participants. The San Diego Population Study en-
olled an ethnically diverse group of men and women who
ere current or former employees of the University of
alifornia, San Diego, and their significant others who were
nvited to participate between 1994 and 1998 in a study of
AD and venous diseases. Briefly, participants were chosen
andomly within age, sex, and ethnicity strata. Age strata
ere 29 to 49 years (primarily 40 to 49 years), 50 to 59 years,
0 to 69 years, and 70 to 91 years (primarily 70 to 79 years).
omen and ethnic minorities (African American, His-
anic, Asian) were oversampled to have adequate power for
ypotheses involving these groups. Additionally, a small
umber of volunteers and their significant others (n  193)
heard about the study, asked to participate, and were
enrolled. The final sample included persons of all levels of
education and occupation and included working, unem-
ployed, and retired persons. Further details of the study have
been published elsewhere (13,19,20).
For all study procedures, participants provided signed,
informed consent after a detailed introduction and descrip-
tion of the study. The study received approval from the
Committee on Investigations Involving Human Subjects at
the University of California, San Diego.
Family history of PAD. Family history of PAD was
obtained via interviewer-administered questionnaire prior to
the ankle brachial index (ABI) measurements. The family
history questionnaire was ascertained by study personnel
who were not performing the ABI measurement and who
were blinded to the vascular examination results. Partici-
pants were asked specifically to exclude foster or adoptive
family members and were asked about PAD history of all
first-degree relatives, including mother, father, brothers,
sisters, sons, and daughters. The exact sequence of questions
was as follows for parental history: “Has your father or
mother ever had any of the following?” and then, “Trouble
with arterial circulation in the legs (peripheral arterial
disease) including bypass surgery in the legs and/or ampu-
tation?” These questions were repeated for brothers, sisters,
sons, and daughters. This questionnaire has not beenvalidated previously for family
history of PAD, which would
involve contact of parents, broth-
ers, sisters, sons, or daughters,
and/or obtaining medical records
of these family members with
regard to PAD. All questions
regarding family history of PAD
can be found in the Online Ap-
pendix. Family history of CVD
also was assessed similarly via
questionnaire and included questions regarding history of
heart attack, stroke, angina, percutaneous transluminal cor-
onary angioplasty, coronary artery bypass graft, and carotid
endarterectomy of first-degree relatives.
ABI measurement. Systolic blood pressure was measured
in both arms with the participant in a supine position.
Continuous-wave Doppler ultrasound was used to measure
systolic blood pressure twice in the posterior tibial artery; in
the rare event that there was no obtainable signal in the
posterior tibial artery, the dorsalis pedis was used. The ABI was
calculated as average systolic blood pressure in the posterior
tibial artery (or dorsalis pedis) divided by the higher of the
systolic blood pressure in the 2 arms. For these analyses, the
worst ABI was used and was defined as the minimum ABI
value of the left and right leg. The higher arm systolic
blood pressure was used because of previous studies
showing a strong association between PAD and subcla-
vian stenosis (21).
Covariates. Age, sex, and race or ethnicity were deter-
mined via questionnaire. Diabetes was defined as self-report
or use of antidiabetic medications or insulin. Current and
past cigarette smoking habits were ascertained via question-
naire, and pack-years of smoking was calculated as the
average number of cigarettes smoked per day over all the
years cigarettes were smoked divided by 20, multiplied by
the total number of years cigarettes were smoked. Smoking
also was defined as ever having smoked versus never having
smoked. Hypertension was defined as a systolic pressure of
140 mm Hg or more or a diastolic pressure of 90 mm Hg or
more, or use of antihypertensive medications. Height (in
centimeters) and weight (in kilograms) were measured, and
the body mass index was calculated as weight in kilograms
divided by height in meters squared. A blood sample was
drawn, and total and high-density lipoprotein (HDL)
cholesterol were measured with standardized laboratory
assays (Beckman Coulter analyzer, Beckman Coulter, Inc.,
Carlsbad, California). Dyslipidemia was defined as a ratio of
total cholesterol to HDL cholesterol of more than 5.0 or use
of hyperlipidemic medications (22).
Statistical analysis. Univariate associations were assessed
using the t test, chi-square test, or Wilcoxon rank sum test.
Because pack-years of smoking was a skewed variable, the
difference between the PAD and non-PAD groups was
assessed using a Wilcoxon rank sum test. All other contin-
Abbreviations
and Acronyms
ABI  ankle brachial index
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
PAD  peripheral artery
diseaseuous variables (i.e., HDL cholesterol and systolic blood
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Family History of PAD and Prevalent PAD September 20, 2011:1386–92pressure) were distributed normally, and thus differences
between the PAD and non-PAD groups for these variables
were assessed using a t test.
To examine the multivariate association of family history
of PAD with prevalent PAD, staged logistic regression
models were used, adding in adjustment variables for
potential confounders and mediators. Family history of
PAD was defined 3 ways: 1) any family history of PAD
(including any first-degree relative); 2) parental history of
PAD (either parent); and 3) number of first-degree relatives
with PAD as a continuous variable. Prevalent PAD was
defined as ABI of 0.90 or less or leg revascularization, and
severe prevalent PAD was defined as ABI of 0.70 or less or
leg revascularization.
To compare associations of family history of PAD and
family history of CVD with prevalent PAD and prevalent
CVD outcomes, we defined family history of CVD or PAD
separately as any parental history. Prevalent CVD was
defined as any previous myocardial infarction, stroke, per-
cutaneous transluminal coronary angioplasty, or coronary
artery bypass graft. Staged logistic regression models also
were used for this analysis.
SAS software version 9.1.3 (SAS Institute, Cary, North
Carolina) was used for all analyses, and p  0.05 was
onsidered statistically significant.
esults
articipant characteristics. A total of 2,376 participants
ad complete ABI and family history data and had an ABI
f 1.4 or less in both legs. Overall, the mean age was 59 
1 years, and 66% were women, 58% were Caucasian, 14%
ere African American, 15% were Hispanic, and 14% were
ther races or ethnicities. There were 87 cases of prevalent
AD, defined as ABI of 0.90 or less or leg revascularization,
nd 44 cases of severe prevalent PAD, defined as ABI of
.70 or less or leg revascularization. PAD prevalence dif-
ered significantly by sex and ethnic group and was signif-
cantly higher in men and African Americans (Table 1).
articipants with prevalent PAD had significantly higher
ystolic blood pressure, total cholesterol, and pack-years of
moking and were more likely ever to have been smokers.
hose with prevalent PAD also were more likely to have
yslipidemia, hypertension, diabetes, and CVD. Partici-
ants with PAD were somewhat more likely to have any
amily history of PAD (p  0.06), but did not differ
ignificantly with regard to parental history of PAD or
arental history of CVD or with regard to the distribution
f the number of first-degree relatives with PAD.
ssociations of family history of PAD with PAD preva-
ence and severity. In the fully adjusted analysis shown in
able 2, any family history of PAD, defined as any
rst-degree relative with PAD, was significantly associated
ith higher odds of PAD (odds ratio [OR]: 1.83, 95%
onfidence interval [CI]: 1.03 to 3.26, p  0.04). Parental
istory of PAD, defined as either mother or father with aAD, similarly was associated with higher odds of PAD
Table 2). Both any family history of PAD and parental
istory of PAD were associated strongly with severe prev-
lent PAD, with approximately 2.4-fold higher odds of
evere PAD for any family history and 2.9-fold higher odds
or parental history of PAD (Table 2). Defining smoking in
ack-years instead of ever smoking or using HDL and total
holesterol instead of dyslipidemia did not change the
esults.
There were no statistically significant interactions of sex
p  0.15), race or ethnicity (p  0.86), body mass index
p  0.20), pack-years of smoking (p  0.41), or ever
moking (p  0.95) with any family history of PAD for
revalent PAD. There was, however, a marginally signifi-
ant interaction of family history with diabetes (p  0.06)
uch that among those with no diabetes, any family history
f PAD was associated significantly with a 6.42-fold higher
dds of prevalent PAD (95% CI: 3.35 to 12.35, p 0.001),
hereas among those with diabetes, any family history of
AD was not associated significantly with prevalent PAD
OR: 1.67, 95% CI: 0.46 to 6.03, p  0.44).
Because participants with prevalent PAD who had un-
ergone a leg revascularization procedure would have been
Baseline Characteristics by PADfor Sa Diego Popula ion Study Cohort*Table 1 B seline Characteristics by PADfor San Diego Population Study Cohort*
Characteristic
No PAD
(n  2,289)
PAD
(n  87) p Value
Age, yrs 59 11 69 10 0.001
Female 1,523 (67%) 45 (52%) 0.004
Ethnicity
Caucasian 1,328 (58%) 56 (64%) 0.001
Hispanic 341 (15%) 6 (7%)
African American 299 (13%) 22 (25%)
Other 321 (14%) 3 (3%)
Ever smoker 1,113 (49%) 60 (69%) 0.001
Pack-years of smoking 0 (0, 10) 15 (0, 45) 0.001
Body mass index, kg/m2 27 5 27 6 0.46
Hypertension 1,057 (46%) 67 (77%) 0.001
Systolic BP, mm Hg 131 20 148 28 0.001
Diastolic BP, mm Hg 77 11 77 12 0.95
Dyslipidemia† 702 (31%) 43 (49%) 0.001
Total cholesterol, mg/dl 210 41 226 54 0.009
HDL cholesterol, mg/dl 54 17 53 18 0.36
Diabetes 129 (6%) 26 (30%) 0.001
Cardiovascular disease 46 (2%) 15 (17%) 0.001
Parental history of CVD‡ 1,366 (60%) 57 (66%) 0.28
Any family history PAD§ 335 (15%) 19 (22%) 0.06
Parental history of PAD‡ 300 (13%) 16 (18%) 0.15
No. of first relatives with PAD§
0 1,954 (85%) 68 (78%) 0.14
1 303 (13%) 18 (21%)
2 32 (1%) 1 (1%)
Values are mean SD, n (%), or median (quartile 1, quartile 3). *Excluding those with ABI1.4 in
ither leg. †Total cholesterol/HDL cholesterol 5.0. ‡Includes mother and father only. §Includes
any first degree relative, that is, mother, father, brothers, sisters, daughters, sons.
ABI ankle brachial index; BP blood pressure; CVD cardiovascular disease; HDL high-density
ipoprotein; PAD  peripheral artery disease.ware of this at the time of the examination interview,
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September 20, 2011:1386–92 Family History of PAD and Prevalent PADwhich could have caused recall bias, we performed a
sensitivity analysis excluding the 10 participants with prev-
alent PAD who had undergone revascularization proce-
dures. Results were very similar—for example, any family
history of PAD was associated with 1.91-fold higher odds
of prevalent PAD (95% CI: 1.04 to 3.52, p  0.04) and
ith a 2.64-fold higher odds of severe prevalent PAD (95%
I: 1.14 to 6.10, p  0.02).
Number of relatives with PAD was associated only
arginally with prevalent PAD. Each increase in the
umber of relatives with PAD (i.e., 0 to 1, 1 to 2, 2 to 3) was
ssociated with a 1.51-fold greater odds of prevalent PAD
95% CI: 0.95 to 2.42, p  0.08). The number of relatives
ith PAD, however, was associated significantly with severe
revalent PAD (OR: 1.91, 95% CI: 1.07 to 3.40, p  0.04)
Table 3).
ssociations of family history of PAD with prevalent
VD and family history of CVD with prevalent PAD.
igure 1 shows associations of parental history of PAD with
revalent CVD, of parental history of CVD with prevalent
AD, and of each with severe prevalent PAD. Associations
ere not statistically significant for parental history of PAD
nd prevalent CVD or for parental history of CVD and
revalent PAD (Fig. 1). The association of parental history
f CVD and severe prevalent PAD was significant in
nadjusted models (OR: 2.03, 95% CI: 1.02 to 4.04, p 
.04) and demographic adjusted models (OR: 2.06, 95% CI:
Association of Family History of PAD With PrevaTable 2 Association of Family History of PA
Any Fami
OR (95% CI)
Prevalent PAD†
Unadjusted 1.63 (0.97–2.75)
 Demographics‡ 1.90 (1.10–3.26)
 Lifestyle/comorbidities§ 1.77 (1.00–3.11)
 SBP, DBP, dyslipidemia 1.83 (1.03–3.26)
Severe prevalent PAD†
Unadjusted 2.18 (1.11–4.28)
 Demographics‡ 2.60 (1.29–5.21)
 Lifestyle/comorbidities§ 2.39 (1.14–5.01)
 SBP, DBP, dyslipidemia 2.42 (1.13–5.23)
*Any family history is any first-degree relative with PAD (mother, fath
having PAD. †PAD is ABI0.90 or leg revascularization; severe prevale
§Adding body mass index, ever smoker, diabetes, hypertension.
CI  confidence interval; DBP  diastolic blood pressure; OR  od
Association of Number of First-Degree RelativesTable 3 Association of Number of First-Degr
Prevalent
OR (95% CI)
Unadjusted 1.37 (0.90–2.09)
 Demographics‡ 1.47 (0.96–1.12)
 Lifestyle/comorbidities§ 1.48 (0.93–2.36)
 SBP, DBP, dyslipidemia 1.51 (0.95–2.42)
*Number of first-degree relatives modeled as a continuous variable. †
ABI 0.70 or leg revascularization. ‡Age, sex, and race or ethnicity. §Adding
Abbreviations as in Tables 1 and 2..02 to 4.17, p  0.04); however, this association was
ttenuated in models adjusted further for comorbidities,
ifestyle factors, blood pressure, and dyslipidemia (Fig. 1).
iscussion
sing a large, ethnically diverse, well-characterized cohort,
e report that having any first-degree relative with PAD
nd parental history of PAD are both associated signifi-
antly with prevalent PAD; these familial associations are
tronger for severe prevalent PAD. The number of first-
egree relatives with PAD is associated marginally with
igher odds of prevalent PAD and is associated significantly
ith higher odds of severe prevalent PAD. Moreover, this
tudy demonstrated that family history of PAD is associated
ore strongly with prevalent PAD than with prevalent
VD, and similarly, that family history of CVD is associ-
ted more strongly with prevalent CVD than with PAD,
uggesting some specificity of the type of family history.
Results of the present study indicate that a significant
enetic component exists for PAD. Studies have shown that
BI, a major criterion for PAD diagnosis, is moderately
eritable, in the range of 0.20 to 0.50 (23–25), but to date,
esults of candidate gene studies and genome-wide associ-
tion studies for ABI or PAD have been mixed, and/or not
ell replicated (15,26). Preliminary evidence suggests that
enes in the inflammatory pathways, the renin-angiotensin
PADth Prevalent PAD
ory* Parents Only*
p Value OR (95% CI) p Value
0.07 1.50 (0.86–2.61) 0.16
0.02 1.88 (1.05–3.35) 0.03
0.05 1.80 (0.99–3.28) 0.06
0.04 1.83 (1.00–3.41) 0.05
0.02 2.22 (1.11–4.43) 0.02
0.008 2.92 (1.42–6.01) 0.004
0.02 2.82 (1.32–6.05) 0.008
0.02 2.91 (1.33–6.40) 0.008
ers, sisters, sons, daughters); parents only is either mother or father
is ABI0.70 or leg revascularization. ‡Age, sex, and race or ethnicity.
; SBP  systolic blood pressure; other abbreviations as in Table 1.
PAD and Prevalent PAD*elatives With PAD and Prevalent PAD*
Severe Prevalent PAD†
p Value OR (95% CI) p Value
0.15 1.70 (1.02–2.82) 0.04
0.08 1.84 (1.10–3.06) 0.02
0.10 1.91 (1.08–3.40) 0.03
0.08 1.91 (1.07–3.40) 0.04
nt PAD is ABI 0.90 or leg revascularization; severe prevalent PAD islentD Wi
ly Hist
er, broth
nt PADWithee R
PAD†
Prevale
body mass index, ever smoker, diabetes, hypertension.
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Family History of PAD and Prevalent PAD September 20, 2011:1386–92pathway, and genes important in nicotine metabolism and
dependence are important determinants of PAD or ABI
(27–30), although it is unclear the extent to which these
associations may be mediated through smoking status or
pack-years of smoking. Previous studies also have suggested
interactions of inflammatory or nicotine dependence genes
with smoking and diabetes, 2 of the major risk factors for
PAD (27,29). In addition to the association of the 9p21
locus with PAD (31), 9q33 also has been implicated
recently, with higher odds for both abdominal aortic aneu-
rysm and PAD (32).
It also is likely true that a complex interplay of genetic
and environmental factors, including smoking, diabetes,
obesity, diet, sex, and racial or ethnic group, lead to the
development of PAD, although we did not find any indi-
cation of interaction of any family history of PAD and ever
smoking, pack-years of smoking, sex, or race or ethnicity for
prevalent PAD in the current study. This is likely because of
the limited power to detect interactions with the relatively
modest number of prevalent PAD cases within each sub-
group in this study. We did find a marginally significant
interaction between any family history of PAD and diabetes
such that family history was associated with much higher
0
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Prevalent CVD
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Figure 1 Association of Parental History of CVD With Prevalent
Model 1 is in blue and represents unadjusted associations. Model 2 is in red and
body mass index, diabetes, and ever smoking. Model 4 is in purple and adjusts fo
vascular disease; PAD  peripheral artery disease.odds of prevalent PAD among those without diabetes ascompared with those with diabetes. This may indicate that
the set of genetic variants involved in diabetes could be
distinct from those involved in PAD; however, these results
should be interpreted with caution given the wide confi-
dence intervals.
Only 2 studies previously have examined the association
of family history of PAD with PAD or symptomatic CVD
(17,18). One study found that participants with a sibling
with premature PAD had 3-fold higher odds of PAD (17).
A second study found that first-degree relatives of individ-
uals with premature PAD had higher odds of early onset
CVD events than relatives of healthy participants (18).
However, these studies were in small, family-based samples
almost exclusively of European descent, only studied pre-
mature onset PAD (age 49 years), or concentrated on
CVD events as an outcome. Results of the current study are
consistent with those of Valentine et al. (17). Our study
extends the literature by showing the association of family
history of PAD with both prevalent PAD and CVD
concurrently, confirming the relationship in a multiethnic
and much larger community-living sample.
Our study suggests that having a parental history of CVD
does not significantly increase the odds of PAD, nor does
tory CVD   and 
ent PAD
Parental History CVD and Severe 
Prevalent PAD
and Parental History of PAD With Prevalent CVD
ts for age, sex, and ethnicity. Model 3 is in green and adjusts for model 2 plus
el 3 plus systolic and diastolic blood pressures and dyslipidemia. CVD  cardio-al His
Preval
PAD
adjus
r modhaving a parental history of PAD significantly increase the
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Valentine et al. (18), who found that first-degree relatives of
individuals with premature PAD had higher odds of early
onset CVD events than relatives of healthy participants;
however, the present study was not restricted to premature
PAD cases. Our differing results could be the result of a lack
of specificity of family history of CVD for PAD or vice
versa. They also could be the result of the heterogeneity
inherent in complex chronic diseases such as CVD and
PAD or the genetic heterogeneity in these diseases. In this
regard, traditional risk factors do not entirely overlap for
PAD and CVD; some traditional risk factors such as
smoking and diabetes are stronger for PAD than CVD (2).
Genetic risk factors also do not seem to overlap entirely or
to be consistent findings in all studies of PAD and CVD,
suggesting that some genetic factors exclusive to PAD may
exist. One study did find 9p21, a well-replicated locus for
congenital heart disease and myocardial infarction (33), to
be associated significantly with PAD and ABI after ac-
counting for myocardial infarction (31). However, in an-
other study, 9p21 was associated only marginally with
clinical PAD (34), and after accounting for congenital heart
disease, the association was no longer marginally significant.
Study strengths and limitations. The San Diego Popula-
tion Study is a population-based cohort of ethnically diverse
men and women with a large age range and was designed
specifically to study PAD. Careful ABI measurement was
performed by trained vascular technicians, and ascertain-
ment of other traditional risk factors was standard and
complete. The current study also did not restrict the
definition of PAD to premature PAD only, but sought to
examine whether family history of PAD was important
factors despite age at onset and despite severity of PAD.
The study also has important limitations. Family history of
PAD and CVD was obtained via an interview-administered
questionnaire, which can result in misclassification, but this
likely would result in bias toward the null hypothesis.
However, information on family history was obtained be-
fore the ABI measurement to avoid recall bias. Results are
from an actively employed and retired population, and so
may not generalize fully to the overall population.
Conclusions
We found that family history of PAD was associated
significantly with PAD, but not with CVD. To date,
significant genetic risk factors for PAD are ORs generally in
the range of 1.1 to 1.3. Currently, familial aggregation
seems to be the most strongly associated genetic risk factor
for PAD, with an OR similar in magnitude to those of
smoking, hypertension, and diabetes, all of which range
from 2- to 4-fold greater odds for PAD (2). This finding
also suggests that asking about family history of PAD
specifically (rather than CVD) may be more useful to
identify individuals at risk for PAD. Based on these find-
ings, future studies are warranted to identify genetic loci,gene or environment interactions, or a combination thereof
that may contribute to development of PAD.
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APPENDIX
For all questions regarding family history of PAD,
please see the online version of this article.
